Loading…
A joint venture of Grand Pharmaceutical (via China Grand Enterprise) subscribed for approximately 1.0431 million preferred shares of Conavi Medical Inc for about $7.5 million. The joint venture also obtained exclusive distribution rights for Conavi's Foresight ICE and Novasight Hybrid products in Greater China for 20 years.
“根据认购协议,合营公司将累计认购约104.31万股Conavi的优先股,代价约750万美元。”beta.zhitongcaijing.com
Summarized from public sources; check the original articles before acting on it.